BLASUBCUTANEOUSINJECTABLE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYMPAVZI (marstacimab-hncq) is a monoclonal antibody approved by the FDA in October 2024 for subcutaneous injection. The drug targets a specific pathway in blood coagulation and is designed for patients with bleeding disorders. Mechanism of action and approved indications are currently under clinical characterization.
Growth
Early-stage product in growth phase with moderate competitive pressure (30% intensity); brand and market access teams should expect rapid scaling of commercial infrastructure over the next 12–24 months.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Started Oct 2025
50 enrolled
Hemophilia A or B
Career Relevance
Joining the HYMPAVZI team offers exposure to a newly launched, growth-stage biologic in the hemostasis space with significant commercial upside. Early-career professionals can build product launch experience and influence market positioning during a critical growth window, while experienced commercial leaders can drive scale-up across payer, provider, and patient channels.
Brand Manager
Worked on HYMPAVZI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.